![](/img/cover-not-exists.png)
PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS
HG Bischoff, A Hermes, DF Heigener, S Cesaro-Tadic, S Walzer, M NuijtenVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(10)72171-9
File:
PDF, 70 KB
english, 2010